Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573071 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1527574 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL377223 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1573282 | 1.00 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL270262 | 0.95 | — | — | |
| SCHEMBL14811180 | 0.89 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL11294538 | 0.84 | TSHR (0.30) | TSHR | |
| SCHEMBL1534459 | 0.83 | CA2 (0.37) | — | |
| SCHEMBL5301936 | 0.83 | ALDH1A1 (0.43) | TSHR | |
| SCHEMBL17537501 | 0.83 | HSD17B10 (0.36) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-8741883-B2 | Compounds and methods for the diagnosis and treatment of amyloid associated diseases | The Regents of the University of California—San Diego (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2018165-B1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100178282-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-15 | — | — | US | disclosed |
| US-7666886-B2 | 2-(p-aminophenyl)-benzothiazole derivatives; radioactive material contains deuterium, tritium; diagnosing, preventing or alleviating the symptoms of Alzheimer's disease; diagnostic imaging of A-beta fibrils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666886-B2 | 2-(p-aminophenyl)-benzothiazole derivatives; radioactive material contains deuterium, tritium; diagnosing, preventing or alleviating the symptoms of Alzheimer's disease; diagnostic imaging of A-beta fibrils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| EP-2018165-A1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | Sanofi-Aventis (FR) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007080325-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
| US-20070066665-A1 | Compounds and methods for the diagnosis and treatment of amyloid associated diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2007-03-22 | — | — | US | disclosed |
| WO-2007011834-A2 | COMPOUNDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-25 | — | — | WO | disclosed |
| US-5136033-A | Ion selective fluorogenic reagents | ALLIED-SIGNAL INC. (US) | 1992-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066665-A1 | Compounds and methods for the diagnosis and treatment of amyloid associated diseases | APP, APBA1, BACE1 | MEN1 1796/4885KMT2A 4303/4885TSHR 4716/4885 |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | MEN1 621/4885KMT2A 3395/4885TSHR 156/4885 |
| US-20100178282-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | APP, APBA1, BACE1 | MEN1 1796/4885KMT2A 4303/4885TSHR 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.